Grifols (GRF.MC) Osake Kurssi
Grifols Kurssi
Liikevaihto on kasvanut 13,8 % vuodessa viimeisten 19 vuoden aikana 7,52 Mrd. EUR:een. Osakekohtainen tulos on kasvanut 9,4 % vuodessa viimeisten 19 vuoden aikana. Grifolsn nettomarginaali on nyt 5,3 %, pääosin vakaa 5,4 %:sta muutama vuosi sitten. Grifolsn osinkotuotto on tällä hetkellä noin 1,55 %. Jakosuhde on noin 26 % tuloksesta. Osinko on kasvanut 9,3 % vuodessa viimeisten 18 vuoden aikana. Analyytikoiden mediaanitavoitehinta on 15,94 EUR, eli yli nykyhintaa 64,6 %. 21 analyytikosta 15 suosittaa ostoa — kokonaiskonsensus on Osta.
Grifols osakekurssi
Grifols liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Grifols -osakkeesta
Grifols SA is a leading global healthcare company focused on improving the health and well-being of people worldwide. The business model of Grifols SA revolves around three main pillars. First, they are engaged in the research, development, production, and sale of plasma-derived products, including immunoglobulins, coagulation factors, and albumin. Second, their diagnostic division offers a comprehensive range of tests and instruments for clinical laboratories. Finally, Grifols SA operates a network of plasma donor centers to collect the raw material used in their plasma-derived therapies. By combining these three elements, Grifols SA ensures a sustainable and efficient business model to provide life-saving therapies to patients and contribute to the advancement of healthcare.
Grifols SA is primarily active in the healthcare industry. The company specializes in the production of plasma-derived medicines, diagnostic systems, and hospital supplies. Grifols SA operates globally, providing a wide range of products and services to healthcare professionals, hospitals, and patients. With a strong presence in the field of transfusion medicine, Grifols SA is known for its contributions in plasma therapies, blood banking, and clinical testing. As a leading player in the healthcare sector, Grifols SA maintains a commitment to advancing treatments, improving patient care, and enhancing scientific research in collaboration with healthcare professionals worldwide.
The main competitors of Grifols SA in the market include multinational pharmaceutical companies such as CSL Limited, Octapharma AG, and Takeda Pharmaceutical Company Limited.
Grifols SA is a multinational pharmaceutical and chemical company based in Spain. Established in 1940 by Dr. José Antonio Grifols Roig, the company began as a small laboratory in Barcelona. Over the years, Grifols SA has grown into a global leader in the production of plasma-derived medicines, diagnostics, and hospital supplies. Their focus on innovation, research, and development has led to numerous breakthroughs in the healthcare industry. With a strong commitment to improving patients' lives, Grifols SA has expanded its operations worldwide and currently operates in more than 100 countries. Their dedication to quality and patient care has earned them a reputable position in the healthcare sector.
Grifols SA, a renowned global healthcare company, has accomplished several significant milestones over the years. One notable achievement is its successful development and production of life-saving plasma medicines, including immunoglobulins, factor VIII, and albumin. Additionally, Grifols SA has pioneered the advancements in transfusion medicine, playing a vital role in blood purification techniques. Furthermore, the company has expanded its reach by acquiring and integrating other renowned pharmaceutical companies such as Talecris Biotherapeutics and Nat-Bioplasma. Grifols SA continues to innovate and provide critical healthcare solutions worldwide, solidifying its position as a leading player in the industry.
Grifols SA primarily operates in various countries and regions worldwide. The company has a significant presence in Spain, where it is headquartered. Additionally, Grifols has expanded its operations to other countries, including the United States, Canada, Mexico, Germany, Italy, France, the United Kingdom, Australia, Japan, and China, among others. With a global footprint, Grifols aims to provide its products and services to a diverse range of markets, contributing to its growth and success in the pharmaceutical and healthcare industry.
As a leading global healthcare company, Grifols SA values innovation, excellence, and a strong commitment to improving patients' lives. Their corporate philosophy centers around three key pillars: commitment to patients, scientific research, and sustainable development. Grifols SA strives to provide high-quality therapies and products, ensuring patient safety and meeting the evolving needs of healthcare professionals worldwide. With a focus on research and development, they aim to advance scientific knowledge and enhance treatment options. Additionally, Grifols SA prioritizes sustainability and responsible business practices, contributing to the well-being of society and the environment.
Analyytikot asettavat tällä hetkellä Grifols-osakkeelle keskimääräisen tavoitehinnan 15,91 EUR (mediaani: 15,94 EUR), mikä merkitsee +64,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 21 analyytikkoarvioon.
21 analyytikkoa arvioi tällä hetkellä Grifols-osaketta: 15 suosittaa ostoa, 4 pitoa ja 2 myyntiä. Vuodelle 2026 analyytikot odottavat Grifols-yhtiöltä 7,64 Mrd. EUR liikevaihtoa ja 0,84 EUR osakekohtaista tulosta.
Grifols-osake (GRF.MC) on listattuna 10 pörssissä, muun muassa: London (0RDU.L), SIX (Zürich) (GRF.SW), Frankfurt (OZTA.F), München (OZTA.MU), Düsseldorf (OZTA.DU), Wien (GRF.VI), Madrid (GRF.MC).
Grifols SA is a leading international company in the field of medical diagnostics and therapy. Founded in 1940, the company is based in Barcelona, Spain, and employs over 18,000 people worldwide. Grifols operates in four business areas: Bioscience, Diagnostics, Hospital, and Raw Materials. Each of these business areas offers a variety of products and services. In the Bioscience business area, Grifols is a global leader in the production of plasma proteins and biopharmaceuticals used in the treatment of serious diseases such as Alpha-1 antitrypsin deficiency, immunodeficiency, hemophilia, and thrombosis. Grifols' products are available in over 100 countries worldwide. In the Diagnostics area, Grifols develops and manufactures diagnostic tests for blood group determination, disease monitoring, and infection diagnostics. Grifols' products are used in clinical laboratories and blood banks worldwide. In the Hospital business area, Grifols offers a comprehensive range of products and services for transfusion, immunotherapy, and clinical nutrition. The company produces infusion solutions, injection products, plasma extraction devices, and clinical nutrition products. The Raw Materials business area includes the production and processing of raw materials for all of Grifols' business areas. Grifols is a global leader in the production of plasma proteins and has one of the most extensive plasma sources worldwide. Grifols is committed to offering products and services of the highest quality and continuously advancing product development. The company invests over 400 million euros in research and development every year. In addition, Grifols operates an extensive global marketing and sales organization to ensure that its products and services are available in all regions worldwide. The company works closely with regulatory authorities and regulatory institutions to ensure that its products meet the highest international standards. Overall, Grifols' business model is focused on offering high-quality products and services in various areas of medical diagnostics and therapy. With its wide range of products, strong global presence, and continuous investments in research and development, the company is well positioned to succeed in an increasingly competitive environment.
odotettu liikevaihto Grifols on 7,64 Mrd. EUR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Grifols on 576,26 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Grifols:n hinta-voitto-suhde (P/E) on tällä hetkellä 11,56. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Grifols-osakkeen arvostusta.
Grifols:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,87. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Grifols-osakkeen arvostuskennuslukuna.
Grifols:n Eulpool-laatuscore on 6/10.
Grifols:n ISIN on ES0171996087. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Grifols:n WKN on A2ABUQ. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Grifols:n ticker on GRF.MC. Tämä pörssinoteeraus käytetään Grifols-osakkeiden kauppaan pörssissä.
Grifols osake
Grifols vertaisryhmä
Grifols Ticker
Grifols FIGI
Kaikki tunnusluvut ja syvällinen analyysi Grifols:sta
Meidän osakeanalyysimme Grifols-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Grifols:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: